Related Experiment Video

Updated: Jun 19, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small

Xuechao Yang1,2, Shu Zhang2,3, Yang Yang4

  • 1College of Biomedical Industry, Guilin Medical University, Guilin, Guangxi, China.

Technology in Cancer Research & Treatment
|July 25, 2024
PubMed

Insights

VT204, a novel KRASG12C inhibitor, effectively reduced non-small cell lung cancer (NSCLC) cell proliferation and tumor growth. This agent shows promise for treating NSCLC with KRASG12C mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
  • Targeting the KRASG12C mutation is a key strategy for NSCLC treatment.
  • Developing effective KRASG12C inhibitors is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the therapeutic potential of VT204, a small molecule inhibitor, against NSCLC.
  • To investigate the in vitro and in vivo efficacy of VT204 in NSCLC models.
  • To elucidate the mechanisms of action of VT204 in NSCLC cells.

Main Methods:

  • In vitro studies assessed VT204's effects on NCI-H358 cell proliferation, apoptosis, cell cycle, migration, and invasion.
  • The RAF/MEK/ERK signaling pathway modulation by VT204 was investigated.
  • In vivo xenograft models were used to evaluate VT204's impact on tumor growth.

Main Results:

  • VT204 significantly suppressed NCI-H358 cell proliferation and colony formation.
  • VT204 inhibited migration and invasion, indicating anti-metastatic potential.
  • VT204 induced apoptosis, G2M cell cycle arrest, and reduced ERK phosphorylation.
  • In vivo studies confirmed VT204's tumor growth inhibitory effects.

Conclusions:

  • VT204 demonstrates significant anti-cancer activity against NSCLC cells harboring the KRASG12C mutation.
  • VT204 exhibits potential as a therapeutic agent for NSCLC treatment.
  • Further investigation of VT204 is warranted for clinical development.
Keywords:
KRASG12CVT204non-small cell lung cancersmall molecule inhibitortherapeutic intervention

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Detection of Lung Tumor Progression in Mice by Ultrasound Imaging04:43

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

6.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K